Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Portfolio Pulse from
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series on January 29, 2025. The company is a clinical-stage biotech firm focusing on cancer therapeutics using its INTASYL® siRNA gene silencing technology.
January 22, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals is set to participate in a virtual roadshow, which could increase visibility and investor interest in its cancer therapeutics technology.
Participation in the roadshow can enhance Phio's visibility among investors, potentially leading to increased interest and positive sentiment towards its stock. The focus on their INTASYL® siRNA technology, which is designed to enhance immune cell effectiveness against cancer, is a key selling point that could attract attention.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100